Sarepta Therapeutics (Formerly known as AVI BioPharma, Inc.) to Present Company Overview at Upcoming Conferences

CAMBRIDGE, MA--(Marketwired - May 10, 2013) - Sarepta Therapeutics (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, announced today that it is scheduled to present at the following investor conferences in May. Chris Garabedian, Sarepta's president and chief executive officer, will be the presenter.

• UBS Global Healthcare Conference in New York, NY on Tuesday, May 21, 2013 at 8:30 a.m. Eastern Time.
• Deutsche Bank's 38th Annual dbAccess Healthcare Conference in Boston, MA on Thursday, May 30, 2012 at 2:50pm Eastern Time.

The presentations will be webcast live on the investor relations section of Sarepta Therapeutics' website at www.sareptatherapeutics.com and will be archived under the events and presentations section following the presentation for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Sarepta Therapeutics

Sarepta Therapeutics is focused on developing first-in-class RNA-based therapeutics to improve and save the lives of people affected by serious and life-threatening rare and infectious diseases. The Company's diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy, as well as potential treatments for some of the world's most lethal infectious diseases. Sarepta aims to build a leading, independent biotech company dedicated to translating its RNA-based science into transformational therapeutics for patients who face significant unmet medical needs. For more information, please visit us at www.sareptatherapeutics.com.